Meeting
2015 ASCO Annual Meeting
Phase 1 trial of brentuximab vedotin in combination with gemcitabine for pediatric and young adult patients with relapsed or refractory Hodgkin lymphoma, a Children’s Oncology Group report.
Authors
Peter D. Cole
The Children's Hospital at Montefiore, Bronx, NY
Peter D. Cole , Monika Metzger , Richard A. Drachtman , Terzah M. Horton , Xiaowei Liu , Charlotte H. Ahern , Charles Minard , Elizabeth Fox , Susan Blaney , Brenda Weigel , Kara M. Kelly
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lymphoma and Plasma Cell Disorders
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Lymphoma
Clinical Trial Registration Number
NCT01780662
Citation
J Clin Oncol 33, 2015 (suppl; abstr 8544)
DOI
10.1200/jco.2015.33.15_suppl.8544
Abstract #
8544
Poster Bd #
361
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Phase 2 trial of brentuximab vedotin and gemcitabine for pediatric and young adult patients with relapsed or refractory Hodgkin lymphoma (HL): A Children’s Oncology Group (COG) report.
First Author: Peter D. Cole
Poster
2023 ASCO Annual Meeting
A phase 1b study of crizotinib in combination with temsirolimus in pediatric ALK- or MET-aberrated relapsed or refractory neuroblastoma (ITCC-053): Results of the phase 1 part.
First Author: Kim Schellekens
Poster
2015 ASCO Annual Meeting
A phase I study of gemcitabine and bendamustine in relapsed/refractory Hodgkin's lymphoma.
First Author: Jonathon Brett Cohen
Poster
2015 ASCO Annual Meeting
A phase I trial of lenalidomide maintenance after autologous stem cell transplant (ASCT) in patients with high-risk relapsed/refractory lymphomas.
First Author: Jakub Svoboda